Purpose: We performed nerve-sparing robot-assisted radical cystectomy (nsRARC) and compared the operative outcomes of nsRARC and open radical cystectomy (ORC).
INTRODUCTION
Open radical cystectomy (ORC) is currently regarded the gold standard for the management of muscle-invasive bladder cancer, extensive uncontrollable non-muscle-invasive cancer, and refractory carcinoma in situ (CIS). 1 Multiple studies have repeatedly demonstrated the feasibility and oncologic efficacy of ORC. [2] [3] [4] [5] However, despite the operative results obtained, this technique is associated with significant morbidity and negative effects on quality of life, which include incontinence and erectile dysfunction. [6] [7] [8] Robot-assisted radical cystectomy (RARC) is being increasingly adopted as a minimally invasive alternative to ORC. [9] [10] [11] RARC has become the main treatment option for bladder cancer worldwide and has been widely applied to improve operative outcomes. [12] [13] [14] More recently, several surgeons have re- For these reasons, RARC preserves neurovascular bundles more effectively and enables anastomotic suture placement in narrow operative spaces without external loupes or a headlight.
We have performed nerve-sparing RARC (nsRARC) at our institution. Here, we describe our technique of nsRARC and report perioperative, oncologic, and functional outcomes.
MATERIALS AND METHODS

Patients
We retrospectively analyzed the data of 38 patients that un- rates, and oncologic outcomes were included in the analysis.
Surgical techniques
The nsRARC was performed using a 6-port transperitoneal approach and a 4-arm da Vinci Si robotic system. In brief, with a patient placed on the operating Small penetrating arteries are secured with titanium clips. The posterior aspect of the prostate is dissected using a completely lateral approach, leaving Denonvillier's fascia in place. ORC was performed through a midline incision in the traditional manner.
All patients underwent extracorporeal urinary diversions. A 5-to 7-cm midline incision below the umbilicus is made for specimen removal and urinary diversion. In case of an ileal conduit, uretero-ileal anastomosis is performed over 6F double J stents using a 4-0 polydioxanone suture, and the distal end of the conduit is fashioned as a stoma at the right port site of the robot arm in Robot cases. Orthotopic neobladders were only applied in nsRARC and performed using the Studer method and ureteral stents. Urethro-enteric continuous anastomosis is then performed intracorporeally after redocking the robotic system.
A Jackson-Pratt drain is placed in the pelvic cavity and around the uretero-enteric anastomosis site. The drain and ureteral stents are removed 2-3 weeks after surgery.
Definition of erection function recovery
Erection function recovery was defined as the ability to achieve penetration ≥50% of the time and to maintain an erection significant enough for penetration ≥50% of the time, as per questions 2 and 3 of the International Index of Erectile Function (IIEF)-5 survey, at 12 months after surgery.
Follow-up evaluation
Patients were reviewed at 4 weeks after surgery, and checked by a renal ultrasound at 2 weeks after stent removal, by computed tomography at 3 and 6 months after surgery, and then at 6-month intervals. At these visits, they underwent a clinical examination, and hemoglobin, electrolytes, creatinine, chloride, bicarbonate, and urethral washing cytology tests were conducted.
Statistical analysis
Demographics and perioperative outcomes were analyzed using the chi-square test and the Mann-Whitney test. The chi-square test was used to analyze erectile function recovery rates at the above-mentioned times. Five-year overall survival and cancer-specific survival were determined using the Kaplan-Meier method. The analysis was performed using PASW Statistics ver. 18.0 (SPSS Inc., Chicago, IL, USA).
Statistical significance was accepted for p values of ＜0.05.
RESULTS
No significant differences were found between the nsRARC and ORC groups in terms of gender, sex, body mass index, American Society of Anesthesiologists physical status classification and clinical stage. However, some operative parameters were found to be significantly different in the 2 study groups. and in 6 patients (26.1%) in the ORC group (ileus in 3, wound disruption in 2, and acute pyelonephritis in 1) ( Table 1 ).
According to the classification, 15 all complications were grade I or II and all cases were managed conservatively.
In the nsRARC group, median follow-up was 80 months.
Cancer recurrence occurred in 4 patients between 1 and 4 months after surgery, in a lung in all 4 cases. Two of these 4 patients died at 2 and 5 months after surgery, respectively.
In the other 2 patients, recurrence occurred at 1 and 4 months, and they survived until 40 and 31 months. After nsRARC, 5-year overall survival and cancer-specific survival were 86.7%
and 86.7%, respectively ( Table 2 ).
In the ORC group, median follow-up was 42 months. Cancer recurrence occurred in 10 patients between 1 and 21 months;
in a lung in 8 cases and a lymph node in 2 cases. Six of these and survived between 41 and 50 months. After ORC, 5-year overall survival and cancer-specific survival rates were 77.7%
and 86.7%, respectively (Table 2) .
With respect to erectile function, overall postoperative potency rates at 12 months after surgery in the nsRARC and ORC groups were 40.0% and 9.5%, respectively, and this difference was significant (p=0.021) ( Table 1) . Nevertheless, erectile dysfunction and sexual dysfunction are important complications of cystectomy and urinary diversion. [6] [7] [8] In a prospective study, Hekal et al. 17 concluded erectile recovery was better and progressively returned to normal in a nerve sparing group, and Schoenberg et al. 18 reported return of sexual function was more likely in younger patients.
DISCUSSION
Menon et al. 19 in a feasibility study on nsRARC first reported that the procedure combines the oncological concepts of open surgery with the technical nuances of robotic surgery.
According to Karolinska Institute experience, the oncologic and functional outcomes and the complications of nsRARC are similar to those of ORC. 20 However, Canda et al. 21 found only one of 11 preoperatively potent men remained potent after a relatively short follow-up of 9-month post-ORC. Haberman et al. 22 concluded nsRARC enabled better recovery of potency without sacrificing oncologic outcomes even in patients with high risk disease as compared with historical open or laparoscopic series.
In the present study, preoperative potency was not evaluated and postoperative potency was assessed at 12 months after surgery using questions 2 and 3 of the IIEF-5 survey. The erection potency rate was excellent (40%) in the nsRARC group as compared with the 9.5% observed in the ORC group.
Recent studies have improved understanding of the pelvic neuroanatomy from the aortic bifurcation to the membranous urethra, and as a result, pelvic nerve preservation during uro-oncologic surgery has been improved. 23, 24 The autonomic nerve supplies afferents to the corpora cavernosa from the pelvic plexus, and these nerve fibers run directly beneath the distal ureter, medial to the umbilical artery, alongside the lateral aspects of seminal vesicles, and adjacent to the prostatic capsule. Recently studies have reported short-term complication rates of from 30% to 69.0% for RARC and long-term complication rates from 34% to 100%. In the present study, the overall complication rate was 30% and no major complication was encountered. 26 The nsRARC is expected to indication for younger patients and advanced age who wants to preserve sexual function.
Generally, nerve sparing radical cystectomy is regarded to present risks of an increase in positive surgical margins and local disease recurrence. However, in the present study, there is no local recurrence. Furthermore, the high negative soft tissue surgical margin rate (100%) achieved suggests that our technique of nsRARC leads to satisfactory local control.
This study has some limitations that should be considered.
First, no comparison was made between nsRARC and conventional RARC. Second, there is no data whatever on preoperative sexual function. Third, our results are inherently limited the single-center, retrospective design of the study and its small sample size. Nevertheless, the study shows that nsRARC produces satisfactory oncologic outcomes with secure local control, and suggests nsRARC better enables recovery of erectile dysfunction than ORC.
CONCLUSIONS
Our clinical experiences indicate nsRARC in selected patients is a feasible procedure in terms of its oncologic outcomes and ability to preserve erectile function relatively effectively.
We believe that this technique has the potential to be adopted by urologic surgeons as a standard RARC procedure.
